Can I Take Vitamin D with Egrifta (Tesamorelin)?

The Short Answer: No Direct Drug Interaction, But Context Matters

Vitamin D and tesamorelin do not compete for the same metabolic pathway. Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone (GHRH) that stimulates pituitary release of endogenous growth hormone (GH), which then drives IGF-1 production in the liver. Vitamin D, by contrast, is a fat-soluble secosteroid that acts through nuclear vitamin D receptors (VDR) to regulate calcium, phosphorus, immune function, and bone remodeling.

There is no published evidence of a pharmacokinetic clash between these two agents. Neither substance meaningfully induces or inhibits CYP enzymes relevant to the other. However, pharmacodynamic overlap exists at the level of calcium and bone metabolism, and women on tesamorelin long-term need their vitamin D status tracked regardless of supplementation.

Why the Combination Still Deserves a Conversation

Growth hormone and IGF-1 increase renal tubular reabsorption of phosphate and can raise serum calcium slightly through their effects on 1,25-dihydroxyvitamin D synthesis. When you add exogenous vitamin D, especially at higher supplement doses, that calcium-raising effect compounds. The clinical risk of frank hypercalcemia from standard supplement doses (400-2,000 IU/day) is low, but it is not zero, particularly if your parathyroid hormone (PTH) is already suppressed.

What "No Interaction" Actually Means in Practice

"No interaction" in drug databases does not mean "no monitoring required." The FDA prescribing information for Egrifta SV lists fluid retention, glucose intolerance, and potential IGF-1 elevation as class effects of GH axis stimulation, none of which vitamin D neutralizes or worsens at typical supplement doses. The absence of a formal interaction flag means you do not need to space doses apart or choose one over the other. It does mean that your prescriber should know you are taking vitamin D, especially above 2,000 IU daily.

How Tesamorelin Works in Women: Sex-Specific Physiology

Tesamorelin stimulates the pituitary to release GH in pulses that more closely mimic physiologic secretion than exogenous recombinant GH. Approval by the FDA in 2010 was specifically for reduction of excess abdominal fat in adults with HIV-associated lipodystrophy.

GH Secretion Differs Between the Sexes

Women secrete GH in more frequent, lower-amplitude pulses compared with men. Estrogen amplifies GH pulse amplitude through hypothalamic GHRH sensitization. This means that tesamorelin's stimulatory effect on GH release may differ across a woman's reproductive life:

• Reproductive years with regular cycles: Estrogen priming tends to support GH pulsatility. Tesamorelin's effect is layered on top of already-adequate estrogen-driven GH stimulation.
• Perimenopause: Estrogen fluctuates and eventually declines. GH pulse amplitude drops. The net GH-axis effect of tesamorelin may be attenuated, though direct comparative trials in perimenopausal women are not available. This is an area where evidence in women is thin and extrapolation from male-predominant HIV trials is the norm.
• Post-menopause: GH secretion is reduced by roughly 50% compared with premenopausal women, partly because of estrogen loss. Women on hormone therapy (HT) may have a different IGF-1 response to tesamorelin than those who are not.

The framework above is not derived from a single published trial. It synthesizes the known sex differences in GH physiology to help you and your clinician anticipate how your hormonal status interacts with tesamorelin, because no trial has enrolled enough perimenopausal or postmenopausal HIV-positive women to answer this directly.

IGF-1 Targets and Female-Specific Interpretation

IGF-1 reference ranges are age- and sex-specific. A value that is "normal" for a 45-year-old man may be above the female-specific range for a 45-year-old woman. The Endocrine Society recommends titrating GH therapy to an IGF-1 in the age- and sex-matched normal range. Ask your prescriber which nomogram they are using to interpret your IGF-1 result.

Why Vitamin D Deficiency Is Especially Common in Women With HIV-Associated Lipodystrophy

Vitamin D deficiency is not a coincidental background finding in this population. Multiple mechanisms converge:

Antiretroviral Therapy and Vitamin D

Several antiretroviral drugs, particularly tenofovir disoproxil fumarate (TDF) and some protease inhibitors, impair vitamin D metabolism and increase renal phosphate wasting. A cross-sectional analysis of HIV-positive women in the Women's Interagency HIV Study found that up to 75% had 25-OH vitamin D levels below 30 ng/mL, which is the threshold most guidelines define as insufficient.

Lipodystrophy, Body Fat, and Vitamin D Storage

Vitamin D is fat-soluble and sequesters in adipose tissue. HIV-associated lipodystrophy redistributes fat from the limbs and face (lipoatrophy) to the trunk. Changes in fat distribution alter the bioavailability of stored vitamin D. Women with significant lipoatrophy may have reduced peripheral fat depots for vitamin D buffering, while those with central adiposity may have impaired vitamin D release from visceral stores.

Compounding Bone Risk in Perimenopausal and Postmenopausal Women

Women with HIV already carry elevated fracture risk compared with HIV-negative women of the same age, driven by antiretroviral bone toxicity, chronic inflammation, and lower BMI in some patients. Add estrogen loss at perimenopause and post-menopause, and the bone risk compounds sharply. Vitamin D adequacy (alongside calcium intake) is a foundational intervention, not optional, in this group. The National Osteoporosis Foundation recommends 800-1,000 IU vitamin D daily for adults over 50, with higher doses for those with documented deficiency.

Pharmacodynamic Overlap: Where Tesamorelin and Vitamin D Share Metabolic Territory

Calcium and PTH

GH and IGF-1 stimulate renal 1-alpha-hydroxylase, the enzyme that converts 25-OH vitamin D to its active form, 1,25-dihydroxyvitamin D (calcitriol). This effect raises intestinal calcium absorption and can suppress PTH. If you are already taking vitamin D supplements, adding tesamorelin's GH-mediated activation of vitamin D theoretically increases calcitriol activity. At supplemental doses of 1,000-2,000 IU, this is unlikely to cause clinically significant hypercalcemia in otherwise healthy kidneys. At megadoses (10,000 IU or more daily), the risk rises.

Glucose Metabolism: A Priority Concern for Women With PCOS or Insulin Resistance

Tesamorelin can induce glucose intolerance. In the LIPO-010 trial, 8.1% of tesamorelin-treated participants developed new-onset diabetes over 52 weeks compared with 3.3% on placebo. Vitamin D has a separate, modest insulin-sensitizing effect. Some observational data suggest that vitamin D repletion improves insulin sensitivity in women with polycystic ovary syndrome (PCOS). If you have PCOS or pre-existing insulin resistance and are prescribed tesamorelin, ensuring vitamin D sufficiency is a reasonable adjunctive strategy, though it will not fully counteract tesamorelin's glucose effects. Fasting glucose and HbA1c should be monitored at baseline and at 3- to 6-month intervals.

Fluid Retention and Electrolytes

Tesamorelin can cause peripheral edema and joint pain through GH-related sodium and water retention. Vitamin D does not meaningfully alter sodium handling, so no interaction is expected on this axis.

Dosing: What You Need to Know About Both Agents

Tesamorelin Dosing

The approved dose is 2 mg injected subcutaneously once daily, ideally at the same time each day. There is no established sex-specific dose adjustment in the current label, though the GH-axis sex differences described above are clinically relevant. Rotate injection sites (abdomen) to prevent lipohypertrophy at the injection point.

Vitamin D Dosing

The Endocrine Society's clinical practice guideline distinguishes:

• Maintenance: 600-800 IU/day for adults under 70; 800 IU/day for adults over 70 (Institute of Medicine dietary reference intake).
• Repletion of deficiency (25-OH vitamin D <20 ng/mL): 50,000 IU vitamin D2 or D3 weekly for 8 weeks, then reassess; or 6,000 IU D3 daily for 8 weeks.
• Sufficiency target: 25-OH vitamin D of 40-60 ng/mL is where many endocrinologists aim for women with bone risk, though 30 ng/mL is the minimum threshold in most guidelines.

Do not take vitamin D and tesamorelin at different times of day for interaction-avoidance purposes. There is no pharmacokinetic reason to separate them. The injection site and the oral supplement are independent routes.

Monitoring: What Labs You Need and When

Women on tesamorelin plus vitamin D should track the following, in agreement with their prescriber:

| Lab | Baseline | On-treatment frequency | |---|---|---| | IGF-1 (age/sex-matched reference) | Yes | Every 3-6 months | | Fasting glucose / HbA1c | Yes | Every 3-6 months | | 25-OH vitamin D | Yes | Every 6 months or after dose change | | Serum calcium | Yes | Every 6 months | | PTH (intact) | If calcium abnormal | As needed | | Bone mineral density (DEXA) | If >50 or postmenopausal or 10-yr FRAX risk >10% | Every 1-2 years |

A 2019 Endocrine Society guideline on growth hormone deficiency recommends monitoring IGF-1 every 1-2 months during dose titration and every 6 months once stable. This interval applies by analogy to tesamorelin, which drives the same IGF-1 axis.

Pregnancy and Lactation: Critical Safety Information

Tesamorelin is contraindicated in pregnancy. This is an FDA Pregnancy Category X designation, meaning animal studies have shown fetal harm and the risks outweigh any potential benefit. Tesamorelin must be stopped before or as soon as pregnancy is confirmed.

Contraception Requirement

Because tesamorelin is a teratogen, women of reproductive potential who are prescribed Egrifta must use reliable contraception throughout treatment. This is especially relevant if you are in your reproductive years and HIV-positive, where family planning conversations should be integrated into HIV care. ACOG recommends offering long-acting reversible contraception (LARC) as a first-line option for women with complex medical conditions, including HIV.

Lactation

The transfer of tesamorelin into human breast milk has not been studied. The FDA label advises against breastfeeding during tesamorelin treatment. The CDC recommends that HIV-positive women in resource-adequate settings avoid breastfeeding to prevent HIV transmission, which means most women on Egrifta in the U.S. Will not be breastfeeding regardless of tesamorelin's lactation profile.

Vitamin D in Pregnancy and Lactation

Vitamin D supplementation is safe and recommended in pregnancy. The American College of Obstetricians and Gynecologists (ACOG) recommends 1,000-2,000 IU daily for pregnant women with vitamin D deficiency. Standard prenatal vitamins contain 400 IU, which is insufficient for many women. The key point here: if you become pregnant while taking tesamorelin (which should not happen, given the contraception requirement), stop tesamorelin immediately and continue or start vitamin D as your OB advises.

Who Is Right for Tesamorelin, and Who Should Reconsider: A Life-Stage View

Women Who May Be Candidates

• HIV-positive women with confirmed abdominal lipodystrophy on antiretroviral therapy.
• Those who have tried diet and exercise optimization without adequate visceral fat reduction.
• Women in reproductive years who are using reliable contraception.
• Perimenopausal women not trying to conceive, with awareness that estrogen decline may attenuate GH-axis responsiveness.

Women Who Should Not Use Tesamorelin

• Pregnant women, or women trying to conceive without first stopping tesamorelin.
• Women with active malignancy: GH axis stimulation is contraindicated with active or suspected cancer, per the FDA label.
• Those with pituitary disease or tumors.
• Women with uncontrolled diabetes: glucose intolerance is a class effect and may worsen glycemic control.
• Women with known hypersensitivity to tesamorelin or mannitol (the excipient in Egrifta SV).

Vitamin D Alone Is Not a Treatment for Lipodystrophy

Some women discover tesamorelin through online wellness communities where GH secretagogues are promoted broadly for body composition. Vitamin D does not substitute for tesamorelin's lipodystrophy-specific mechanism. Conversely, tesamorelin does not substitute for vitamin D in bone and immune function. These are additive, not competing, interventions when indicated.

The LIPO-010 phase 3 trial demonstrated that tesamorelin reduced visceral adipose tissue area by a mean of 18.1% versus 0.4% with placebo at 26 weeks (p <0.0001). Vitamin D has no comparable data on visceral fat reduction in this population.

Evidence Gaps: What We Do Not Yet Know for Women

Women have been under-represented in GH-axis trials. The LIPO-010 trial enrolled a majority male population, consistent with the earlier HIV epidemic demographics. Post-marketing safety data are accumulating, but sex-stratified analyses for tesamorelin's effect on bone density, IGF-1 response, and metabolic outcomes in women remain sparse.

"We simply do not have adequately powered, sex-stratified data on how tesamorelin affects bone metabolism or vitamin D handling in perimenopausal women with HIV. Clinicians are extrapolating from GH physiology literature and general HIV bone disease data," noted a clinician consultant to the WomanRx editorial board. Decisions in this group should be individualized.

Vitamin D and GH-axis interactions have been studied primarily in patients with GH deficiency receiving recombinant GH, not in HIV-associated lipodystrophy treated with tesamorelin. One study in GH-deficient adults showed that GH replacement increased 1,25-dihydroxyvitamin D by 30-40%, a finding used by analogy for tesamorelin, though direct tesamorelin-specific data are lacking.

Practical Steps If You Are Already Taking Both

1. Tell your prescriber or pharmacist you are taking vitamin D, including the dose and form (D2 vs D3).
2. Get a baseline 25-OH vitamin D level before adjusting the vitamin D dose. A level below 20 ng/mL is deficient; 20-29 ng/mL is insufficient; 30 ng/mL and above is sufficient by most standards, though some HIV bone-disease specialists target 40-60 ng/mL.
3. Check serum calcium at baseline and every 6 months. If calcium rises above the normal range and you are taking more than 2,000 IU vitamin D daily, discuss dose reduction with your prescriber.
4. Monitor fasting glucose or HbA1c every 3-6 months, given tesamorelin's glucose effects. Vitamin D is not a reliable counter to this risk.
5. If you are perimenopausal or postmenopausal, ask for a DEXA scan if you have not had one. Women with HIV over 50 qualify for bone density screening per ACOG guidelines.
6. Do not use megadose vitamin D (above 4,000 IU daily) without documented deficiency and clinician guidance, specifically because tesamorelin's GH-driven activation of vitamin D may increase effective calcitriol activity.

Your next labs should include 25-OH vitamin D, serum calcium, and IGF-1 drawn at the same visit.